Urgo Medical’s teams strive on a daily basis to meet their commitment to relieve pain, simplify treatments and make life easier for patients.
Today, Urgo Medical offers high-tech solutions for the treatment of serious and incapacitating conditions: burns, pressure sores, leg ulcers, epidermolysis bullosa, diabetic foot ulcers...
With three leading brands: Urgo®, France’s best-selling dressing, Humex®, No. 1 in the upper respiratory tract infection market, and Alvityl®, which tops the children’s vitamin supplement market, Urgo Consumer Healthcare continues to grow thanks to a dynamic innovation policy.
Voted most innovative OTC company in pharmacies in 2008 and revelation of the year at the BFM Awards, Urgo Consumer Healthcare has implemented an original development process designed to bring new products to market quickly. Products that are under two years old account for 22% of its total sales.
With its Filmogel® technology, Urgo is the first pharmaceutical company to have launched a range of liquid dressings:
- Urgo® Mouth Ulcers, the first dressing for the mouth, which has reached the Number 2 spot in France in just two years;
- Urgo® Skin Cracks, the leading treatment for chapped and cracked skin;
- Urgo® Damaged Nails, winner of the Direct Médica trophy for innovation in 2009 for the best retail pharmacy product launch.
A pioneer in the self-service pharmacy segment, Urgo Consumer Healthcare is recognised as the company that has best supported pharmacists in this field.
Anticipating and meeting the needs of its customers is a golden rule at Urgo Consumer Healthcare.
Internationally, Urgo Consumer Healthcare has a strong position in 25 countries and its ultimate aim is to reach the No. 1 spot in all its reference markets in Europe.
Supported by its healing expertise as well as its constant attentiveness to and sound knowledge of both health professionals and patients, Urgo Medical develops high-tech medical solutions for treatments tailored to the various problems encountered in the prevention and treatment of wounds and tissue damage.
In 2000, Urgo Medical revolutionised the wound healing market market by inventing Lipido-Colloid Technology, which gave rise to Urgotul®. In 2007, it did the same again with Cellostart®, the first dressing to restart the healing process.
The leader in France and Germany, Urgo Medical is also the fourth-placed company in the European wound care market as a whole.
Urgo Medical has a second area of expertise: compression systems. Currently No. 1 in the UK compression bandage market, this activity is set to be extended to the whole of Europe, starting with Germany and the Netherlands.
By gaining a foothold in new regions and continuing its intensive research and development programme, Urgo Medical is determined to become the European wound care sector leader.
In 2005, €37million was invested in the new industrial and logistics site at Chevigny-Saint-Sauveur.
Urgo deliberately chose to strengthen the company’s roots in the Burgundy region of France for the industrial production of the innovations resulting from its R&D programmes. This investment strengthens the company’s position as French market leader and acts as a launch pad for its international development.
Urgo is also building its growth through a human resources policy founded on local support and a strong corporate culture.
The key objective: “to foster the development and professional fulfilment of every individual, in order to enhance our performance and grow together”.
Every employee can build his or her own professional career thanks to customised training programmes. Working at Urgo means having the chance to develop skills and take on responsibilities at an early stage.
